NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky, LLP announces that it has commenced an investigation of Ophthotech Corporation (“Ophthotech” or the “Company”) (NASDAQ:OPHT) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On December 12, 2016, Ophthotech announced disappointing results for two phase 3 clinical trials designed to test the Company’s experimental compound Fovista in combination with the drug Lucentis. Following this news, shares of Ophthotech were down more than 85% on intraday trading. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.